Grifols culminates a year of growth and approves the distribution of a record EUR 265 million in dividends

- Shareholders endorse the company's management and approve all items on the agenda

- Grifols' economic performance has centered on profitability and growth diversification, and its increase in shareholder retribution (21.5%) is in line with 2017 results

- The company's management has led to sales increases of its main divisions in all regions where it operates, achieving total revenues of more than EUR 4,300 million (6.6%) and EUR 663 million (21.5%) in net profit

- Grifols continues to place innovation and talent development as top priorities, allocating more than EUR 580 million to capital expenditures and innovation and expanding its staff by 23% to 18,300 employees

- The company optimized its financial structure, leading to an improved average cost of debt and longer maturities following a debt refinancing process

- Grifols co-CEOs have presented the 2017 Corporate Responsibility Report

Barcelona, May 25, 2018.- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global company that enhances the health and well-being of patients through the development of life-saving plasma-derived medicines, clinical diagnostics and pharmaceutical specialties for hospital use, and a forerunner in the research and development of therapeutic alternatives that drive scientific and social progress, held its Annual General Shareholders' Meeting on second call.

The meeting convened 536 shareholders who own 340,396,121 class A shares and represent 79.9% of share capital with voting rights. The votes delegated to the Board represented 75.0% of share capital, confirming shareholders' support of the Group’s management and business plan.
Grifols’ shareholders unanimously endorse the first year of Raimon Grífols Roura and Víctor Grífols Deu at the helm of the group’s management

Grifols grew by 6.6% in 2017 to over EUR 4,300 million in total revenues, with a 21.5% increase in net profit to more than EUR 663 million. The increase in shareholder retribution (21.5%) is in line with 2017 results.

Grifols fulfilled its strategic objectives that guide the company’s overall direction and continued to consolidate its plans to guarantee long-term sustainable growth.

In 2017, Grifols’ financial performance focused on boosting profitability and growth diversification, which translated into increases in sales of its main divisions in all regions where it operates; promoting capital expenditure and innovation by allocating more than EUR 580 million in 2017; integrating the share of the NAT donor-screening technology unit acquired in early 2017 as a means to reinforce its leadership position in transfusional medicine; generating greater net cash flows, achieving a 43% increase to EUR 1,039 million; and optimizing its financial structure through a debt refinancing process that improved the average cost of debt and extended maturities.

In addition to ensuring a path of sustainable growth, the company continues to place innovation and talent development as top priorities.

Grifols allocated more than EUR 311 million in R+D+i in 2017 and more than EUR 1,300 million since 2013. The company’s R+D+i strategy is built on a sustainable, long-term and integrated, focus that includes the development of in-house initiatives, as well as external projects through investee companies whose research complements Grifols’ core activities.

Grifols’ commitment to creating high-quality employment and offering ongoing training and professional development in 2017 led to its recognition as one of the 500 best global employers¹. The company’s employee base grew by 23% to 18,300 employees; of which 58% are under 40 and 57% are women.

In Spain, the number of employees continued its upward trend, closing the year with a 6.3% increase compared to 2016 and a total of 3,645 jobs at the end of 2017. Of note is Grifols’ expanding talent pool in the United States, where it has more than 3,100 employees. In ROW (rest of the world), the number of employees increased by 10%. More than 5,700 people have joined Grifols over the last five years.

Shareholder retribution increases by 21.5% in 2017 to EUR 0.38 per share

Grifols’ shareholders approved the distribution of EUR 265.1 million in dividends (EUR 0.38 gross per share) in 2017, a company record that represents a 21.5% increase over 2016 and reflects the company’s firm commitment to generate value for its shareholders. This total includes the preferred dividend of EUR 0.01 gross associated with each class B share.

¹ According to the annual ranking published by Forbes and Statista.
The dividend will be paid out in two payments: an interim dividend paid in December 2017 of EUR 0.18 gross per share and a second payment of EUR 0.20 gross per share that will be distributed\(^2\) from June 5, 2018 onwards.

The company maintains its pay-out of 40% of the group’s consolidated net profits.

**Corporate Governance**

The shareholders endorsed the appointments of Ms. Belén Villalonga Morenés and Ms. Marla E. Salmon as independent directors.

Grifols promotes a policy of gender balance and industry experience on its board of directors and committees. At present, women comprise more than 30% of Grifols’ board members, surpassing the 2020 objective established by the CNMV Good Governance Code for publicly traded companies. In recent years the group has also bolstered the number of independent directors, which currently account for 54% of total members.

Beyond legal requirement and in compliance with best practices in corporate governance, Grifols’ Board of Directors has a Lead Independent Director responsible for organizing common positions among independent directors to uphold and reinforce independence between the control and the management of the company.

**Corporate Responsibility Report**

Also presented at the General Shareholders’ Meeting was the 2017 Corporate Responsibility Report, approved by the Board of Directors on April 27, 2018 as part of the company’s longstanding commitment to transparency.

The report aims to offer Grifols’ stakeholders a true and comprehensive overview of its social, environmental and economic performance in 2017, within the framework of the commitments assumed in its Corporate Social Responsibility Policy.

The Corporate Responsibility Report was prepared in accordance with the information requirements and guidelines of the Global Reporting Initiative (GRI) and verified by an external independent firm.

**Approval of agenda items**

Key agenda items ratified by the shareholders include:

- Approval of the individual and consolidated annual accounts
- Appointment and re-election of auditors
- Approval of the Annual Directors’ Remuneration report, consultative vote

\(^2\) Paid through Iberclear and its participating entities, with BBVA acting as the payment agent.
About Grifols

Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to help them deliver expert medical care.

Grifols’ three main divisions - Bioscience, Diagnostic and Hospital - develop, produce and market innovative products and services that are available in more than 100 countries.

With a network of 190 plasma donation centers, Grifols is a leading producer of plasma-derived medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.

Grifols is headquartered in Barcelona, Spain and has 18,300 employees in 30 countries.

In 2017, sales exceeded 4,300 million euros. Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).

For more information, visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events.
S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.